Table 2.
Comparative characteristics of 73 patients with sporotrichosis treated with amphotericin B, divided into two groups, HIV coinfected and non-HIV coinfected (FIOCRUZ, Rio de Janeiro, Brazil, 1998–2018).
| Group | HIV Coinfected Patients | Non-HIV Coinfected Patients | p Value | |
|---|---|---|---|---|
| n | 38 | 35 | ||
| Age a | 38.71 [16.18, 55.26] | 55.62 [19.45, 83.95] | <0.001 | |
| Ethnicity | White | 5 (13.2%) | 13 (38.2%) | 0.028 |
| Non-white | 33 (86.8%) | 21 (61.8%) | ||
| Tuberculosis | 11 (28.9%) | 2 (5.7%) | 0.013 | |
| Affected organs and systems | Skin | 38 (100.0%) | 34 (97.1%) | 0.479 |
| Osteoarticular | 25 (65.8%) | 22 (62.9%) | 0.812 | |
| Upper airways | 18 (47.4%) | 13 (37.1%) | 0.478 | |
| CNS | 13 (34.2%) | 0 (0.0%) | - c | |
| Ocular | 5 (13.2%) | 3 (8.6%) | 0.712 | |
| Lungs | 5 (13.2%) | 1 (2.9%) | 0.201 | |
| Amphotericin B indication | Disseminated infection | 34 (89.5%) | 23 (65.7%) | 0.022 |
| Low response to itraconazole | 4 (10.5%) | 12 (34.3%) | ||
| Number of AMB cycles b | 1.00 [1.00, 7.00] | 1.00 [1.00, 2.00] | <0.001 | |
| Amphotericin B total dose b | Deoxycholate | 1465.00 [50.00, 11,250.00] | 400.00 [50.00, 8885.00] | <0.001 |
| Lipid complex | 6600.00 [1900.00, 14,700.00] | 3900.00 [200.00, 11,700.00] | 0.005 | |
| Treatment duration b | 834.50 [1.00, 4017.00] | 484.00 [7.00, 1899.00] | 0.006 | |
| Adverse effects due to AMB | 27 (71.1%) | 16 (45.7%) | 0.034 | |
| Other treatments | Itraconazole | 37 (97.4%) | 33 (94.3%) | 0.604 |
| Terbinafine | 12 (31.6%) | 11 (31.4%) | 1.000 | |
| Posaconazole | 10 (26.3%) | 1 (2.9%) | 0.007 | |
| Low compliance to treatment | 22 (59.5%) | 10 (28.6%) | 0.010 | |
| Anti-Sporothrix antibody detection | Positive | 12 (60.0%) | 13 (92.9%) | 0.050 |
| Negative | 8 (40.0%) | 1 (7.1%) | ||
| Cured | 18 (47.4%) | 20 (57.1%) | 0.553 |
a Mean and range; b Median and range; c p value was not calculated due to zero count for non-HIV coinfected patients. p values < 0.05 are highlighted in bold.